GlassScriptPhysician profile
Son Van Truong
NPI 1659380814
$3,580.92
in general payments reported to CMS, 2019-2025
30 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $456 · 2021: $292 · 2022: $331 · 2023: $375 · 2024: $724 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $866.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $499.59 | 2021-2025 | Imfinzi, Airsupra, Breztri |
| Genzyme Corporation | $421.86 | 2023-2025 | |
| Inspire Medical Systems, INC. | $219.64 | 2023-2024 | Inspire |
| Glaxosmithkline, LLC. | $201.14 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $145.19 | 2021-2023 | |
| Genentech USA, INC. | $130.83 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Libtayo |
| Janssen Pharmaceuticals, INC | $124.33 | 2019 | |
| Insmed, INC. | $121.56 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $101.44 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $95.87 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $63.71 | 2024-2025 | Tezspire, Tavneos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.05 | 2019 | |
| Grifols USA, LLC | $51.57 | 2021-2025 | Prolastin-C Liquid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.69 | 2019-2024 | Ofev |
| Kite Pharma, INC. | $40.34 | 2020-2021 | |
| United Therapeutics Corporation | $39.86 | 2020-2022 | |
| Gilead Sciences, INC. | $35.24 | 2024 | |
| 3b Medical, INC. | $25.11 | 2023 | Luna |
| Ethicon US, LLC | $22.10 | 2019 | |
| Resmed Corp | $20.74 | 2024 | |
| Apria Healthcare LLC | $20.57 | 2021 | |
| Itamar Medical INC | $18.78 | 2021 | |
| Vapotherm INC | $18.24 | 2022 | |
| Pfizer INC. | $18.15 | 2022 | |
| Hospira, INC. | $18.03 | 2024 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 | |
| Allergan, INC. | $11.82 | 2019 | |
| Horizon Therapeutics Plc | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.